In this study, given the crucial role of EMT in IPF development and progression, we identified a ranked set of IPF drug targets (AMFR; Autocrine Motility Factor Receptor, MDFIC; MyoD Family Inhibitor Domain Containing and NR5A2; Nuclear Receptor subfamily 5 group A member 2) through Standigm ASKTM and complementary DNA (cDNA) microarray analysis. Here, MDFIC is linked to idiopathic pulmonary fibrosis.